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OBJECTIVES The purpose of this multicenter randomized trial was to compare total mortality during
therapy with amiodarone or an implantable cardioverter-defibrillator (ICD) in patients with
nonischemic dilated cardiomyopathy (NIDCM) and nonsustained ventricular tachycardia
(NSVT).
BACKGROUND Whether an ICD reduces mortality more than amiodarone in patients with NIDCM and
NSVT is unknown.
METHODS One hundred three patients with NIDCM, left ventricular ejection fraction 0.35, and
asymptomatic NSVT were randomized to receive either amiodarone or an ICD. The primary
end point was total mortality. Secondary end points included arrhythmia-free survival, quality
of life, and costs.
RESULTS The study was stopped when the prospective stopping rule for futility was reached. The
percent of patients surviving at one year (90% vs. 96%) and three years (88% vs. 87%) in the
amiodarone and ICD groups, respectively, were not statistically different (p  0.8). Quality
of life was also similar with each therapy (p  NS). There was a trend with amiodarone, as
compared to the ICD, towards improved arrhythmia-free survival (p  0.1) and lower costs
during the first year of therapy ($8,879 vs. $22,039, p  0.1).
CONCLUSIONS Mortality and quality of life in patients with NIDCM and NSVT treated with amiodarone
or an ICD are not statistically different. There is a trend towards a more beneficial cost profile
and improved arrhythmia-free survival with amiodarone therapy. (J Am Coll Cardiol 2003;
41:1707–12) © 2003 by the American College of Cardiology Foundation
The optimal therapy for prevention of sudden death in
patients with nonischemic dilated cardiomyopathy
(NIDCM) and asymptomatic nonsustained ventricular
tachycardia (NSVT) has not been determined. The results
of Grupo de Estudio de la Sobrevida en la Insuficiencia
Cardiaca en Argentina (GESICA) and Survival Trial of
Antiarrhythmic Therapy in Congestive Heart Failure
(CHF-STAT) suggest that amiodarone therapy in patients
See page 1713
with a NIDCM may have a beneficial or neutral effect on
survival (1,2). An implantable cardioverter-defibrillator
(ICD) effectively prevents sudden cardiac death (SCD) and
improves total mortality compared to antiarrhythmic drug
therapy in some patient groups (3–5). However, whether
ICDs also reduce mortality in patients with NIDCM and
asymptomatic NSVT is unknown. Therefore, the purpose
of this multicenter trial was to compare total mortality in
patients with NIDCM and asymptomatic NSVT randomly
assigned to therapy with amiodarone or an ICD.
METHODS
Study design. Ten centers participated in this trial (see
Appendix), and the institutional review boards approved the
study protocol. Subjects were randomly assigned to receive
either amiodarone or an ICD. Randomization was stratified
by center. Patients were enrolled between August 1996 and
September 2000, and follow-up ended June 30, 2001.
Patients who refused study participation were followed in a
voluntary registry.
Inclusion criteria for the study included a NIDCM, an
ejection fraction 0.35, asymptomatic NSVT, New York
Heart Association functional class I to III, and age 18
years. A NIDCM was defined as left ventricular dysfunction
in the absence of coronary artery disease (CAD) or dispro-
portionate to the severity of CAD. Nonsustained VT was
defined as at least three consecutive ventricular premature
depolarizations with a rate 100 beats/min, lasting 30 s
and not associated with symptoms of cerebral hypoperfu-
sion. Optimal medical therapy with angiotensin-converting
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enzyme inhibitors, beta-blockers, and potassium-sparing
diuretics was strongly encouraged and attempted through-
out the duration of the study. Exclusion criteria included
syncope, pregnancy, a contraindication to amiodarone or
defibrillator therapy, or concomitant therapy with a Class I
antiarrhythmic drug.
The primary end point of the study was total mortality.
Secondary end points consisted of SCD, non-SCD, non-
cardiac death, syncope, arrhythmia-free survival, quality of
life, and costs. Arrhythmia-free survival was defined as
freedom from death, syncope, appropriate ICD therapy, and
sustained ventricular tachycardia (VT) or ventricular fibril-
lation (VF). Patients who underwent cardiac transplantation
were censored from data analysis beginning on the day of
transplantation.
Study design rationale. Electrophysiologic testing has not
been found useful for risk stratification in patients with
NIDCM and asymptomatic NSVT (6–8). Therefore, ami-
odarone and the implantable defibrillator were used empir-
ically to determine whether either therapy was more effec-
tive than the other.
A control group was not included because this would
have substantially increased the required sample size, mak-
ing the study less feasible. Furthermore, it was felt that the
absence of a control group would not invalidate the results
of the study. No previous study has demonstrated a negative
effect of amiodarone or an ICD on survival (1–5,9–12).
Therefore, if a difference in mortality between the amioda-
rone and ICD groups was observed, it was felt reasonable to
assume that the mortality difference was not due to a
negative effect of amiodarone or the ICD. On the other
hand, if the two therapies were found to be equivalent, it
was felt that differentiation between a neutral versus an
equally positive effect on survival would be possible based on
analysis of the stored electrograms recorded by the implant-
able defibrillators. If episodes of VT or VF were docu-
mented by the stored electrograms, this would imply that
the patients treated with amiodarone would have experi-
enced similar arrhythmias in the absence of amiodarone.
Sample size calculation. During the anticipated follow-up
duration of two years, the expected total mortality rates were
20% in the patients treated with amiodarone and 10% in the
patients treated with an ICD (1–3). An 80% power to
identify a reduction in total morality from 20% to 10% was
calculated to require 219 patients in each group (p  0.05,
two-sided t test).
Therapy and follow-up. Amiodarone therapy was initiated
at a dose of 800 mg/day. The amiodarone dosage was
decreased to 400 mg/day after seven days and to 300 mg/day
after one year. Among the patients treated with amioda-
rone, thyroid function studies, aspartate and alanine
transaminase plasma levels, and a chest X-ray were obtained
at baseline and every four months during follow-up. Serum
concentrations of amiodarone and desethylamiodarone were
obtained four months and one year after initiation of
amiodarone therapy.
Implantable defibrillators were inserted using conven-
tional non-thoracotomy techniques. A successful implant
was achieved in each patient. Defibrillator follow-up was
performed every four months. This included evaluation of
stored electrograms and sensing and pacing functions. No
patient was lost at follow-up.
Outcome classification. An events committee determined
the causes of death. Each of the three members of the events
committee independently evaluated all information available
regarding each death. To assure a blinded review, all
references to amiodarone or ICD therapy were removed
from the reviewed documents, including the death certifi-
cate, other relevant medical records, and interviews with
family members. The members of the events committee
adjudicated differences in the cause of death and a consensus
was reached. The stored electrograms and all available
clinical data were used to determine the appropriateness of
ICD therapies.
Quality of life. Quality of life was measured using the
Quality of Well Being Schedule and the State Trait Anxiety
Inventory (13,14). Patients completed both questionnaires
at the time of randomization and during follow-up visits.
Cost analysis. Inpatient and outpatient cost data were
collected for the 24 patients who received care within the
University of Michigan Health System. Data from the
University of Michigan Health System cost accounting
system were used. Data were gathered for a one-year
interval, starting at the time at which the patient entered the
trial. There was no attempt to eliminate costs for noncardiac
care. Drug costs, based on wholesale costs, were calculated
only for the drugs for which dosage information was
collected, including amiodarone, beta-blockers, angiotensin
converting enzyme inhibitors, digoxin, diuretics, warfarin,
and aspirin.
Statistical analysis. All analyses were based on intention-
to-treat. Primary and secondary end points were compared
between the two groups with a log-rank test, and survival
curves were constructed using Kaplan-Meier methods.
Continuous variables are expressed as mean  1 SD and
were compared using Student t test, except for comparisons
between baseline and one-year quality-of-life scores within
the two study groups, which were compared with a paired t
test. A chi-squared or Fisher’s exact test was used to
compare nominal variables. A p  0.05 was considered
statistically significant.
A data safety monitoring board evaluated the results every
Abbreviations and Acronyms
CAD  coronary artery disease
ICD  implantable cardioverter-defibrillator
NIDCM  nonischemic dilated cardiomyopathy
NSVT  nonsustained ventricular tachycardia
SCD  sudden cardiac death
VF  ventricular fibrillation
VT  ventricular tachycardia
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10 deaths. Prospectively determined stopping rules con-
sisted of a mortality difference at a significance level of
0.025, or a significance level of 0.025 (90% power)
based on a power calculation conditional on holding out-
comes stable and assuming enrollment of 600 patients.
RESULTS
Patient characteristics. The clinical characteristics of the
patients at the time of enrollment into the study are shown
in Table 1. At the conclusion of the study, the mean
amiodarone dosage for patients randomized to amiodarone
was 303  93 mg/day. The serum concentrations of
amiodarone 4 and 12 months after initiation of amiodarone
therapy were 1.65  0.93 and 1.53  0.77 mg/dl, respec-
tively, and 1.25 0.56 and 1.26 0.46 mg/dl, respectively,
for desethylamiodarone. Concomitant drug therapy at the
last follow-up visit is described in Table 2. The mean
duration of follow-up was 2.0  1.3 years (range 0.1 to 4.8
years).
Main findings. At the first interim analysis in September
2000, the study enrollment was discontinued because the
prospective stopping rule for the inability to demonstrate
statistical significance was reached. The one- and three-year
survival rates among the 52 patients treated with amioda-
rone were 90% and 87%, respectively, compared with 96%
and 88%, respectively, among the 51 patients treated with
an ICD (Fig. 1; p 0.8) . The distribution of sudden versus
non-SCDs was similar between patients treated with ami-
odarone or an ICD (p  0.7; Table 3).
Arrhythmia-free survival rates at one and three years were
82% and 73%, respectively, among the patients treated with
amiodarone (Fig. 2). Among the patients treated with an
ICD, the arrhythmia-free survival rates at one and three
years were 78% and 63%, respectively (p  0.1). Over the
entire duration of the study, 5.8% of the patients treated
with amiodarone and 3.9% of the patients treated with an
ICD (p  0.7) had syncope. Ventricular tachycardia or VF
was the cause of syncope in each patient with an ICD in
whom it occurred. An appropriate ICD therapy was deliv-
ered in 16 patients for ventricular arrhythmias that had a
mean rate of 218  40 beats/min (range 170 to 284
beats/min).
Quality of life assessment. The average values for the
Quality of Well Being Schedule and the State Trait Anxiety
Inventory at baseline and at one year were similar among
patients treated with amiodarone or an ICD (Table 4). At
one year, the Quality of Well Being Schedule and the State
Trait Anxiety Inventory scores were not significantly differ-
ent between patients treated with an ICD who did (67 15
and 73  22, respectively) and did not (68  16 and 82 
31, respectively; both 0.05) receive appropriate ICD
therapies.
Cost analysis. The total cost of medical care in the first
year after entry into the study was $8,879  $27,614 in the
amiodarone group, compared with $22,079  $22,039 in
the ICD group (p  0.1).
Discontinued therapy, crossovers, and complications.
Twenty-five patients initially treated with amiodarone had
the drug discontinued because of adverse side effects 17.8 
13.3 months (range 1.2 to 43.8 months) after initiation of
therapy. An ICD was inserted 26.1  16.9 months after
entry into the study in eight patients initially treated with
amiodarone because of near-syncope with documented VT
(n 2), cardiac arrest (n 2), or amiodarone intolerance (n
 4). Among the cohort of patients treated with a defibril-
lator, one subsequently received amiodarone (200  0
mg/day) for frequent appropriate defibrillator therapies,
eight received amiodarone (200  0 mg/day) for the
treatment of atrial fibrillation, and two received amiodarone
(150  71 mg/day) for other reasons. Three patients
underwent cardiac transplantation (Table 3).
Table 1. Patient Characteristics
Amiodarone ICD p Value
n 52 51 —
Age (yrs) 60  12 58  11 0.5
% Female 26 33 0.3
LVEF 0.23  0.08 0.22  0.10 0.5
Duration of NIDCM (yrs) 3.5  3.9 2.9  4.0 0.6
Diabetes mellitus (%) 36 31 0.6
Hypertension (%) 67 58 0.4
CAD  70% (%) 3/27 (11.0%) 2/41 (4.9%) 0.3
Heart rate (beats/min) 78  14 80  17 0.7
RBBB (%) 8 16 0.2
LBBB (%) 53 42 0.3
NYHA class (%) 0.9
I 13 18
II 63 64
III 24 16
# NSVT beats 12  21 8  7 0.2
NSVT (beats/min) 151  20 160  27 0.4
NSVT identified (%) 0.7
ECG 8 6
Event monitor 29 26
Holter monitor 2 6
Hospital telemetry 61 62
CAD 70%  one major epicardial coronary artery with a 70% or greater stenosis;
ECG  electrocardiogram; ICD  implantable cardioverter-defibrillator; LBBB 
left bundle branch block; LVEF  left ventricular ejection fraction; NIDCM 
nonischemic dilated cardiomyopathy; # NSVT  number of beats of nonsustained
ventricular tachycardia; NSVT identified  technique used to identify nonsustained
ventricular tachycardia; NYHA  New York Heart Association; RBBB  right
bundle branch block.
Table 2. Concomitant Drug Therapy at Last Follow-Up
Amiodarone ICD p Value
Beta-blocker (%) 50 53 0.5
ACE inhibitor (%) 81 90 0.4
Digoxin (%) 67 71 0.5
Diuretic (%) 67 71 0.5
Spironolactone (%) 19 20 0.9
ACE  angiotensin-converting enzyme; ICD  implantable cardioverter-
defibrillator.
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DISCUSSION
Main findings. The three-year survival rate of approxi-
mately 89% was not statistically different among patients
with NIDCM and NSVT who were treated with amioda-
rone or an ICD. There was a trend towards improved
arrhythmia-free survival with amiodarone therapy. The
quality of life with each therapy was not statistically differ-
ent. A trend towards a 60% cost savings was observed with
amiodarone therapy.
Efficacy of amiodarone. In the present study, amiodarone
therapy was associated with a trend towards improved
arrhythmia-free survival. This difference was primarily due
to the frequent occurrence of ventricular arrhythmias with a
mean rate 210 beats/min in the ICD group. Syncope
among the patients treated with an ICD only occurred in
the setting of a treated ventricular arrhythmia. It is likely
that, left untreated, at least some of the ventricular arrhyth-
mias treated by the ICDs would have resulted in syncope or
cardiac arrest. The relatively rapid rate of the ventricular
arrhythmias treated by the ICD, the association of syncope
with ventricular arrhythmias, and the arrhythmia-free sur-
vival rates provide strong evidence that amiodarone and the
ICD had an equally beneficial, as opposed to neutral, effect
on survival. However, arrhythmia-free survival is biased
against the ICD, because asymptomatic tachycardias were
not recognized in the patients treated with amiodarone.
Quality of life. In the present study, neither therapy had a
statistically significant effect on quality of life. Therefore,
the decision to treat with amiodarone or an ICD should not
be influenced by quality-of-life issues in this patient popu-
lation.
Cost analysis. During the first year of treatment, amioda-
rone therapy was associated with costs that were approxi-
mately 60% less than the costs associated with ICD therapy.
This observation trended towards statistical significance.
Other studies have also found the total costs associated with
amiodarone therapy to be much less than treatment with an
ICD (15–17).
Amiodarone, underlying heart disease, and efficacy. In
two prior primary prevention trials among patients with
CAD, the ICD was associated with improved survival
compared to pharmacologic therapy, which was generally
amiodarone (3,4). In the present study, the one- and
three-year mortality rates in both groups were approxi-
mately the same as the mortality rates associated with ICD
therapy in MADIT and MUSTT, and substantially better
than the mortality rates associated with pharmacologic
therapy, essentially amiodarone, in those trials (3,4). This
suggests that amiodarone may be more effective in prevent-
ing death among patients with NIDCM than among
patients with CAD.
Early study termination. Trial designs typically include a
prospective stopping rule for futility. The mortality rates in the
present study were less than expected in both groups. The
lower-than-expected mortality rates may be partially attribut-
able to concomitant medical therapy with angiotensin-
Figure 1. Kaplan-Meier estimates of cumulative survival among patients treated with amiodarone (solid line) or an implantable defibrillator (dotted
line).
Table 3. Deaths and Transplants
Amiodarone ICD p Value
n 52 51 —
# Deaths (%) 7 (13.5) 6 (11.8) 0.8
# Cardiac deaths (%) 5 (71) 4 (67) 0.9
# SCD (%) 2 (40) 1 (25) 0.7
# Non-SCD (%) 3 (60) 3 (75) 0.7
# Noncardiac (%) 2 (29) 2 (33) 0.9
# Cardiac transplant (%) 2 (4) 1 (2) 0.8
Duration of follow-up (yrs) 1.8  1.4 2.2  1.2 0.4
ICD  implantable cardioverter-defibrillator; SCD  sudden cardiac death.
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converting enzyme inhibitors, spironolactone, and beta-
blockers (18–25).
Discontinuation of amiodarone and crossovers. Amioda-
rone was discontinued in approximately a third of patients
in the present study. This is a lower rate than was observed
in MADIT (3). However, this may be the reality of treating
patients with amiodarone. The use of an intention to treat
analysis mitigates some of the effects of discontinued or
crossover therapy. The clinical implication is that when
faced with a patient who has a NIDCM and asymptomatic
NSVT, initial therapy with amiodarone is associated with a
similar mortality rate as initial therapy with an ICD.
Previous studies. Only one previous published study has
addressed the value of an ICD at preventing SCD in
patients with a NIDCM (26). In this previous study, 104
patients with new onset NIDCM, without documented
ventricular arrhythmias were randomized to standard med-
ical therapy or an ICD. Patients treated with an ICD did
not have improved survival compared with patients treated
with standard medical therapy. This previous study is
different from the present study in at least two important
ways. First, only patients with new-onset NIDCM were
included. The present study excluded patients with newly
diagnosed NIDCM. Patients with new-onset NIDCM may
be at lower risk for SCD than patients with an established
NIDCM. Second, the previous trial included patients irre-
spective of ventricular arrhythmias (26). The present study
had inclusion criteria that included asymptomatic NSVT.
Limitations. The major limitation of this trial is that there
was not a control group of patients treated neither with
amiodarone nor an ICD. This raises the possibility that the
addition of either amiodarone or an ICD to standard
medical therapy may not have incremental value. However,
given the improvement in arrhythmia-free survival with
amiodarone, this seems unlikely. The second important
limitation is sample size. Post hoc power calculations permit
detection of the observed mortality differences with a power
of 3%. This suggests that important statistical differences
between amiodarone and defibrillator therapy may still exist.
However, with the observed mortality rates, approximately
12,000 patients would have been required to achieve a
power of 80%.
Clinical implications. In all prior primary or secondary
prevention trials, the ICD was felt to be more effective than
pharmacologic therapy in prolonging survival (3–5,11,12).
The results of these studies have fueled the dramatic growth
in the use of ICDs in the U.S. over the past few years (27).
Although most or all of the subjects in these prior trials had
CAD, there has been a strong tendency in clinical practice
to apply the results to all patients potentially at risk of
sudden death. The present study seems to represent a
departure from the usual interpretation of superiority of the
ICD over amiodarone demonstrated in previous studies
(3–5,11,12). Not only was total mortality found not to be
statistically different with amiodarone and ICD in patients
with NIDCM and NSVT, but there was also a trend
Figure 2. Kaplan-Meier estimates of arrhythmia-free survival among patients treated with amiodarone (solid line) or an implantable cardioverter-
defibrillator (dotted line).
Table 4. Quality of Life Scores
Amiodarone ICD p Value
Quality of Well-Being Schedule*
Baseline 70  17 67  15 0.5
1 year 70  22 74  19 0.5
p Value 0.9 0.2
State Trait Anxiety Inventory†
Baseline 79  21 75  25 0.5
1 year 67  20 61  17 0.4
p Value 0.1 0.1
*The score range is 0 to 110. A higher level of general well-being is associated with
a greater value. †The score range is 40 to 160. A greater value is associated with a
lower level of anxiety.
ICD  implantable cardioverter-defibrillator.
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towards amiodarone being more effective than the ICD in
preventing symptomatic VT.
The lack of statistically different survival rates and the
trend towards a substantial cost savings with amiodarone
provide an argument favoring amiodarone as the initial
therapy to prevent death among patients with NIDCM and
NSVT.
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